Angina pectoris and intensive intravenous iron treatment in hemodialysis patients

Hippokratia 2007, 11(1):30-34

P Malindretos, A Sioulis, E Avgeriou, A Michalaki, V Roma, D Grekas
1st Dpt Internal Medicine, Renal Unit, AHEPA University Hospital, Thessaloniki, Greece


Background: Intravenous iron and erythropoietin are commonly used for the treatment of anemia in end stage renal disease (ESRD) patients. Even though i.v. iron is proven to be very effective, there is great concern regarding its possible toxic effects. The aim of our study was to evaluate the possible correlation between iron administration and the incidence of angina pectoris in hemodialysis patients.
Methods: The study sample consisted of 10 stable coronary heart disease patients, receiving chronic hemodialysis treatment. The patients followed consecutively three different i.v. iron dose regimens according to their needs. Their standard monthly laboratory measurements were correlated with the incidence of angina pectoris and i.v. iron treatment.
Results: Hematocrit, ferritin, serum iron and mean rhEPO dose were related to the total amount of administered iron. Angina pectoris was related to intensive iron treatment, age and platelet count. Total white blood cell count were related to hemodialysis duration, platelet count and serum triglycerides.
Conclusion: It is suggested that the intensive intravenous iron treatment (300 mg / week) is associated with the increased incidence of angina pectoris in stable coronary heart disease patients receiving hemodialysis.

Keywords: coronary heart disease, angina pectoris, intravenous iron, erythropoietin, ESRD

Correspoding author: Grekas D, e-mail: